Barchart.com
[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Ultragenyx Pharmaceu (RARE)

Ultragenyx Pharmaceu (RARE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Ultragenyx to Participate at Bank of America’s 2026 Healthcare Conference GlobeNewswire - Wed May 6, 3:30PM CDT

NOVATO, Calif., May 06, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious...

RARE : 24.48 (-2.08%)
Ultragenyx: Q1 Earnings Snapshot AP - Tue May 5, 3:07PM CDT

Ultragenyx: Q1 Earnings Snapshot

RARE : 24.48 (-2.08%)
Ultragenyx Reports First Quarter 2026 Financial Results and Corporate Update GlobeNewswire - Tue May 5, 3:01PM CDT

First quarter total revenue of $136 million, Crysvita® revenue of $93 million and Dojolvi® revenue of $18 million Reaffirm 2026 financial guidance, including total revenue of $730 million to $760...

RARE : 24.48 (-2.08%)
Ultragenyx's Conference Call Tomorrow: Still Waiting for Gene Therapy to Pay Rent Barchart - Mon May 4, 4:26PM CDT

Barchart Research What to Expect from RARE Earnings RARE Generated May 4, 2026 Current Price $24.81 EPS Estimate $$-1.55 Consensus Rating Strong Buy Average Move 5.39% Ultragenyx's Conference Call Tomorrow:...

RARE : 24.48 (-2.08%)
Ultragenyx to Host Conference Call for First Quarter 2026 Financial Results and Corporate Update GlobeNewswire - Wed Apr 29, 7:00AM CDT

NOVATO, Calif., April 29, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious...

RARE : 24.48 (-2.08%)
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire - Fri Apr 24, 3:30PM CDT

NOVATO, Calif., April 24, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare...

RARE : 24.48 (-2.08%)
RARE FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Ultragenyx Pharmaceutical (RARE) Investors of Securities Class Action Deadline on April 6, 2026 Business Wire - Mon Apr 6, 8:26AM CDT

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Ultragenyx To Contact Him Directly To Discuss Their...

RARE : 24.48 (-2.08%)
RARE Investors Have Opportunity to Lead Ultragenyx Pharmaceutical Inc. Securities Fraud Lawsuit with the Schall Law Firm PR Newswire - Mon Apr 6, 2:44AM CDT

LOS ANGELES , April 6, 2026 /PRNewswire/ --  The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Ultragenyx Pharmaceutical...

RARE : 24.48 (-2.08%)
Ultragenyx Pharmaceutical Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - RARE PR Newswire - Mon Apr 6, 1:24AM CDT

LOS ANGELES , April 6, 2026 /PRNewswire/ --  The DJS Law Group reminds investors of a class action lawsuit against Ultragenyx Pharmaceutical Inc. ("Ultragenyx" or "the Company") (NASDAQ: RARE...

RARE : 24.48 (-2.08%)
RARE Deadline: RARE Investors with Losses in Excess of $100K Have Opportunity to Lead Ultragenyx Pharmaceutical Inc. Securities Fraud Lawsuit PR Newswire - Sat Apr 4, 3:00PM CDT

NEW YORK , April 4, 2026 /PRNewswire/ --

RARE : 24.48 (-2.08%)

Barchart Exclusives

Cathie Wood Snatches Up $46.4 Million of the Hottest AI IPO of the Year. Here’s Why. Barchart - 27 minutes ago
Cathie Wood just made a massive bet on the AI chip startup, Cerebras, that is challenging Nvidia. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.